




### Company description

Formycon is an expert company for the development of Biosimilar Medicines, covering all stages of biopharmaceutical development from analytics and cell line development to preclinical and clinical studies, all the way to the preparation of regulatory submission documents.

Formycon develops Biosimilars for the rapidly growing disease areas of ophthalmology, immunology, and immuno-oncology, as well as for other key chronic diseases. The company's

pipeline includes FYB201 (reference medicine Lucentis®), which has already been approved and launched in the US, Europe and further territories, the late-stage biosimilar candidates FYB202 (reference medicine Stelara®) and FYB203 (reference medicine Eylea®), as well as FYB206 (reference medicine Keytruda®), a biosimilar candidate in an advanced pre-clinical development phase. The two preclinical biosimilar candidates FYB208 and FYB209 complete Formycon's biosimilar pipeline.

## Formycon Development pipeline



### Strategy and goals

Through their proven efficacy, cost-efficiency and high quality standard, biosimilars make an important contribution to providing patients with access to effective medical treatments. At the same time, they help to reduce the financial burden on global healthcare systems.

With the launch of FYB201 in the U.S., Europe, the U.K. and other territories the company has become a commercial-stage biotech company focused on biosimilars. Through the transaction with ATHOS KG in spring 2022 with the acquisition of the biosimilar asset FYB201 at 50% and of the biosimilar asset FYB202 at 100%, the stage has also been set for a significant increase of the participation in future marketing revenues.

Formycon plans to primarily invest the resulting cash inflows into the expansion of its product development pipeline growing towards becoming a fully integrated pharmaceutical company in the biosimilar segment.

### Contact

**Sabrina Müller**  
Director Investor Relations and  
Corporate Communications  
ir@formycon.com

[www.formycon.com](http://www.formycon.com)



#### Eckdaten

Founded: 2012  
Headquarters: Planegg / Munich  
Employees: > 230

#### Management Board

Dr. Stefan Glombitza (CEO)  
Nicola Mikulcic (CBO)  
Dr. Andreas Seidl (CSO)  
Enno Spillner (CFO)

#### Supervisory Board

Dr. Olaf Stiller (Chairman)  
Peter Wendeln (Deputy Chairman)  
Klaus Röhrig (Member)  
Wolfgang Essler (Member)

#### Market data

ISIN: DE000A1EWVY8  
Market Segment: Frankfurt, Stock Exchange „Scale“  
Market Capitalization: ~ € 1.0 billion  
Outstanding Shares: 17,656,902

#### Shareholder Structure

- = 58 % Anchor Investors incl. Athos KG, Active Ownership Capital, Wendeln & Cie. KG, Gedeon Richter, DSP
- = 06 % Founders & Management
- = 36 % Free Float (as defined by Deutsche Börse)



#### Key financials (in € million)

	2018	2019	2020*	2021*	2022*
Revenue	43.0	33.2	34.3	36.6	42.5
EBITDA	8.0	-1.4	-5.2	-12.6	-15.9
Net Income	7.1	-2.3	-6.7	-13.3	36.0
Equity Ratio (in %)	83.9	90.0	90.0	85.0	41.8

#### Formycon News

<https://www.formycon.com/en/news-media/press-releases/>



Keytruda® is a registered trademark of Merck Sharp & Dohme LLC; Stelara® is a registered trademark of Johnson & Johnson; Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc.; Lucentis® is a registered trademark of Genentech, Inc.

\*According to IFRS

2024/02

This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.